https://www.thebodypro.com/category/dolutegravir-tivicay/tag/conference-coverage
Dolutegravir (Tivicay)

Conference Coverage

The Latest

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Dolutegravir Monotherapy: Still No Longer Recommended in Either Research or Clinical Practice Img

Dolutegravir Monotherapy: Still No Longer Recommended in Either Research or Clinical Practice

Although treatment guidelines since 2016 recommend against further research into the use of dolutegravir monotherapy, it was disconcerting to have two oral presentations at AIDS 2018 reporting studies that still continued after the 2016 recommendatio...

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin Img

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

Dolutegravir/3TC Dual Therapy as Switch Option in Multiple Studies Img

Dolutegravir/3TC Dual Therapy as Switch Option in Multiple Studies

Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.

Dolutegravir Outperforms Lopinavir/Ritonavir Second-Line: Interim Results From the DAWNING Study Img

Dolutegravir Outperforms Lopinavir/Ritonavir Second-Line: Interim Results From the DAWNING Study

Dolutegravir (DTG) was superior to lopinavir/ritonavir (LPV/r) in a comparison of DTG-based regimen versus the WHO-recommended second-line regimen.

Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity Img

Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity

Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.

Promo Image

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Two-Drug HIV Treatment Regimens Effective in Latest Studies Img

Two-Drug HIV Treatment Regimens Effective in Latest Studies

"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.